Roche NimbleGen will work with Beijing-based CapitalBio to develop instruments and products to enhance and automate its microarray workflow for use in preventive and personalized diagnostics, the firms said last week.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.